Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
April 06, 2023 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
March 13, 2023 07:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
March 10, 2023 19:10 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Provides Statement About SVB

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
March 03, 2023 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 28, 2023 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatinInitiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate,...
February 21, 2023 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 03, 2023 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 02, 2023 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 01, 2023 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...